On 17 November 2026, Carlsberg Group announced the successful capital raise of EUR 20 million for Traitomic in a Series A round led by Sofinnova Partners, with participation from EIFO, The Footprint firm, PSV Hafnium, Nordic Foodtech VC, and SVG Ventures.
Traitomic was established by Carlsberg Group to commercialise its patented non-GM trait development technology for applications beyond brewing. Since its inception, Traitomic has built the world’s largest commercial trait portfolio, serving a global base of blue-chip clients across the food, agriculture, and biotech industries. The investor consortium, led by Sofinnova Partners, together with the capital raised, will support the continued development of Traitomic and accelerate its commercial growth.
ABG Sundal Collier is proud to have acted as exclusive financial advisor to Carlsberg Group and Traitomic in connection with the transaction.